Nature Communications

“The WFPB induced a clinically significant reduction in LDL-C relative to the SAD”

study authors, Nature Communications

A randomized, controlled crossover feeding trial, but only 50 participants and four-week arms in a genetic-disease population, so durability outside the feeding lab is untested.

In the brief: Plant-based diet cuts LDL 17.9% in genetic high-cholesterol trial → (plant-based diet[tiab] OR vegan diet[tiab] OR vegans[tiab]) AND →

“The WFPB induced a clinically significant reduction in LDL-C relative to the SAD”

study authors, Nature Communications

A randomized, fully controlled crossover feeding trial in 50 genetically confirmed patients, with results the authors call clinically significant enough to reestablish diet as a frontline therapy.

In the brief: Whole-food plant-based diet cuts LDL cholesterol 17.9% in genetic high-cholesterol trial → Primary Sources →

“The WFPB induced a clinically significant reduction in LDL-C relative to the SAD (−17.9%, 95% CI: −21.7%, −14.3%; P < 0.0001)”

Nature Communications, familial hypercholesterolemia crossover trial

This is a peer-reviewed, fully controlled feeding trial with a genetically confirmed patient population, though the sample is small (50 adults) and industry-funded dairy-consulting ties exist for one author unrelated to the diet arm.

In the brief: Whole-food plant-based diet cuts LDL 17.9% in genetic high-cholesterol trial → (plant-based diet[tiab] OR vegan diet[tiab] OR vegans[tiab]) AND →